Neurocognitive disorders in DSM-5

American Journal of Psychiatry

Volumn 170, Issue 6, 2013, Pages 585-587

  Blazer, Dan ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; TAU PROTEIN;

ADL DISABILITY; ALZHEIMER DISEASE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DEMENTIA; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DSM-5; DSM-IV; FUNCTIONAL DISEASE; HUMAN; HUNTINGTON CHOREA; LEARNING DISORDER; MEMORY DISORDER; NEUROCOGNITIVE DISORDER; NEUROLOGIC DISEASE; NEUROPSYCHOLOGICAL TEST; NOTE; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; PROGNOSIS; SUBSTANCE ABUSE; SYMPTOMATOLOGY; TRAUMATIC BRAIN INJURY; ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; GENETIC MARKER; MILD COGNITIVE IMPAIRMENT; PSYCHOLOGICAL ASPECT;

ALZHEIMER DISEASE; COGNITION DISORDERS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; GENETIC MARKERS; HUMANS; MILD COGNITIVE IMPAIRMENT;

EID: 84882273174     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2013.13020179     Document Type: Note

References (9)

1. Ganguli M, Blacker D, Blazer DG, Grant I, Jeste DV, Paulsen JS, Petersen RC, Sachdev PS: Classification of neurocognitive disorders in DSM-5: a work in progress. Am J Geriatr Psychiatry 2011; 19: 205-210
2. Morris JC: Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. Arch Neurol 2012; 69: 700-708
3. Span P: Time to recognize mild cognitive disorder? New York Times, January 25, 2013. http://newoldage.blogs. nytimes.com/2013/01/25/time-to- recognize-mild-cognitive-disorder/
4. Petersen RC: Clinical practice: mild cognitive impairment. N Engl J Med 2011; 364: 2227-2234
5. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Ab42 in humans. Ann Neurol 2006; 59: 512-519
6. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-319
7. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative: Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-413
8. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-279
9. Rascovsky K, Hodges JR, Kipps CM, Johnson JK, Seeley WW, Mendez MF, Knopman D, Kertesz A, Mesulam M, Salmon DP, Galasko D, Chow TW, Decarli C, Hillis A, Josephs K, Kramer JH, Weintraub S, Grossman M, Gorno- Tempini ML, Miller BM: Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Dis Assoc Disord 2007; 21:S14-S18